- Exchange: NASDAQ CM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Discovery Laboratories Inc
+ Add to WatchlistDSCO:US
1.6000 USD 0.0300 1.84%As of 20:10:00 ET on 05/24/2013.
Snapshot for Discovery Laboratories Inc (DSCO)
| Open: | 1.6200 | Day's Range: | 1.6000 - 1.6500 | Volume: | 329,656 |
|---|---|---|---|---|---|
| Previous Close: | 1.6000 | 52wk Range: | 1.5000 - 3.5100 | 1-Yr Rtn: | -37.50% |
Key Statistics for DSCO
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.9200 |
| Est. EPS (USD) (12/2013) | -0.9370 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 85.22 |
| Shares Outstanding (M) | 53.26 |
| 30 Day Average Volume | 614,603 |
| Price/Book (mrq) | 7.4044 |
| Price/Sale (ttm) | 261.0193 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for DSCO
Company Profile & Key Executives for DSCO
Discovery Laboratories, Inc. is a biopharmaceutical company that develops its proprietary surfactant technology as Surfactant Replacement Therapies (SRT) for respiratory diseases. Through this technology, pulmonary surfactants have the potential to be developed into a series of respiratory therapies for patients in the neonatal care unit, critical care unit and other hospital settings.
| John R LeoneChairman | John G CooperPresident/CEO/CFO |
| Thomas F MillerSenior VP/COO | Russell ClaytonSenior VP:Research And Dev |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
DSCO News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page